[go: up one dir, main page]

TR200200928T2 - 2-pyrazoline-5-on compositions - Google Patents

2-pyrazoline-5-on compositions

Info

Publication number
TR200200928T2
TR200200928T2 TR2002/00928T TR200200928T TR200200928T2 TR 200200928 T2 TR200200928 T2 TR 200200928T2 TR 2002/00928 T TR2002/00928 T TR 2002/00928T TR 200200928 T TR200200928 T TR 200200928T TR 200200928 T2 TR200200928 T2 TR 200200928T2
Authority
TR
Turkey
Prior art keywords
compositions
pyrazoline
chemical compositions
angiogenesis
threonine
Prior art date
Application number
TR2002/00928T
Other languages
Turkish (tr)
Inventor
M. Moset Marina
Maria Castellano Berlanga Jose
F.Fernandez Isabel
J.Calderwood David
Rafferty Paul
D.Arnold Lee
Original Assignee
Abbott Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co.Kg filed Critical Abbott Gmbh & Co.Kg
Publication of TR200200928T2 publication Critical patent/TR200200928T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

(I) yapisal formülünü haiz kimyasal terkipler ve fizyolojik olarak kabul edilebilir tuzlari serin/treonin ve tirosin kinaz etkinliginin engelleyicileridir.Etkinlikleri bu kimyasal terkipler tarafindan engellenen birçok tirosin kinaz anjiyogenik süreçlere katilir. Böylece bu kimyasal terkipler anjiyogenezin veya endotelyal hücre çogalmasinin etken oldugu hastalik durumlarini iyilestirebilir.Bu terkipler kanser ve hiperproliferatif bozukluklarin da tedavisinde kullanilabilir.Chemical compositions and physiologically acceptable salts of structural formula (I) are inhibitors of serine / threonine and tyrosine kinase activity. Thus, these chemical compositions can improve disease conditions caused by angiogenesis or endothelial cell proliferation. These compositions can also be used in the treatment of cancer and hyperproliferative disorders.

TR2002/00928T 1999-07-30 2000-07-28 2-pyrazoline-5-on compositions TR200200928T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14656399P 1999-07-30 1999-07-30

Publications (1)

Publication Number Publication Date
TR200200928T2 true TR200200928T2 (en) 2002-09-23

Family

ID=22517965

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00928T TR200200928T2 (en) 1999-07-30 2000-07-28 2-pyrazoline-5-on compositions

Country Status (21)

Country Link
EP (1) EP1218373A2 (en)
JP (1) JP2003506368A (en)
KR (1) KR20020091829A (en)
CN (1) CN1193026C (en)
AR (1) AR032279A1 (en)
AU (1) AU6388900A (en)
BG (1) BG106392A (en)
BR (1) BR0012896A (en)
CA (1) CA2380644A1 (en)
CZ (1) CZ2002302A3 (en)
HK (1) HK1049154A1 (en)
HU (1) HUP0400540A3 (en)
IL (1) IL147757A0 (en)
MX (1) MXPA02001088A (en)
NO (1) NO20020487L (en)
NZ (1) NZ516850A (en)
PL (1) PL354144A1 (en)
SK (1) SK1512002A3 (en)
TR (1) TR200200928T2 (en)
WO (1) WO2001009121A2 (en)
ZA (1) ZA200200477B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
WO2003011287A1 (en) * 2001-08-03 2003-02-13 Vertex Pharmaceuticals Incorporated Pyrazolon derivatives as inhibitors of gsk-3
WO2005002574A1 (en) * 2003-06-24 2005-01-13 Actelion Pharmaceuticals Ltd Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
JPWO2005012255A1 (en) * 2003-08-01 2006-09-14 三菱ウェルファーマ株式会社 Treatment for inflammatory joint diseases
EP1681063A4 (en) * 2003-10-14 2009-08-05 Satoshi Takeo AGENT FOR ATTENUATING MENTAL DISORDERS
ES2527118T3 (en) 2003-12-19 2015-01-20 Plexxikon Inc. Ret modulator development compounds and procedures
GB0329617D0 (en) * 2003-12-23 2004-01-28 Astex Technology Ltd Pharmaceutical compounds
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
WO2006124874A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
JPWO2006129583A1 (en) * 2005-05-30 2009-01-08 株式会社ジーンケア研究所 Pyrazolone derivatives
EP1900728A1 (en) * 2005-05-30 2008-03-19 Genecare Research Institute Co., Ltd Pharmaceutical composition comprising pyrazolone derivative
US7371862B2 (en) 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
DE102005057924A1 (en) 2005-12-05 2007-06-06 Merck Patent Gmbh pyridazinone derivatives
CN101336247B (en) 2005-12-09 2013-01-23 豪夫迈·罗氏有限公司 Antiviral nucleosides
PL2084174T3 (en) 2006-10-10 2013-12-31 Gilead Pharmasset Llc Preparation of nucleosides ribofuranosyl pyrimidines
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2170830B1 (en) 2007-07-17 2014-10-15 Plexxikon, Inc. 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS
KR100987557B1 (en) * 2008-03-18 2010-10-12 이화여자대학교 산학협력단 Compositions for treating or preventing vascular restenosis
US9145424B2 (en) 2008-11-20 2015-09-29 Northwestern University Treatment of amyotrophic lateral sclerosis
EP2367798B1 (en) * 2008-11-20 2018-02-28 Northwestern University Pyrazolone derivatives useful in the treatment of amyotrophic lateral sclerosis
MX2011006892A (en) 2008-12-23 2011-07-20 Pharmasset Inc Synthesis of purine nucleosides.
KR20170058465A (en) 2009-04-03 2017-05-26 에프. 호프만-라 로슈 아게 Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (en) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
BR112012012156A2 (en) 2009-11-06 2015-09-08 Plexxikon Inc compounds and methods for kinase modulation, and indications for this
AU2011235044A1 (en) 2010-03-31 2012-11-22 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
MY162950A (en) 2011-02-07 2017-07-31 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (en) 2011-02-21 2013-09-18 Plexxikon Inc SOLID FORMS OF {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDE OF PROPANE ACID-1- SULFONIC
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
KR101684955B1 (en) * 2012-07-23 2016-12-12 주식회사유한양행 Furan-containing fused cyclic compound or its salt and pharmaceutical composition comprising the same
SG11201606149YA (en) 2014-02-14 2016-09-29 Inception 2 Inc Pyrazolone compounds and uses thereof
CN105037269B (en) * 2015-07-10 2018-01-19 中国人民解放军第二军医大学 Substituted pyrazolecarboxylic ketone secretory protease inhibitors and preparation method thereof
PH12020500343B1 (en) 2017-08-15 2024-02-21 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in treating blood disorders
KR102625224B1 (en) * 2018-10-31 2024-01-15 주식회사 큐로젠 Composition for preventing, improving or treating autoimmune diseases comprising pyrazol-one derivatives
CN111793032B (en) * 2019-04-08 2021-11-19 四川省中医药科学院 Pyrazolone compounds and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369310A (en) * 1979-11-19 1983-01-18 Ciba-Geigy Ltd. Bleachable dyes
JPH078851B2 (en) * 1985-07-29 1995-02-01 鐘淵化学工業株式会社 3-phenylthiomethylstyrene derivative
JPS6229570A (en) * 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd 3,5-diisopropylbenzylidene heterocyclic compound
JP2678822B2 (en) * 1990-06-04 1997-11-19 富士写真フイルム株式会社 Silver halide photographic material

Also Published As

Publication number Publication date
AU6388900A (en) 2001-02-19
CZ2002302A3 (en) 2002-06-12
NO20020487D0 (en) 2002-01-30
NO20020487L (en) 2002-03-12
PL354144A1 (en) 2003-12-29
EP1218373A2 (en) 2002-07-03
CA2380644A1 (en) 2001-02-08
BG106392A (en) 2002-12-29
IL147757A0 (en) 2002-08-14
HK1049154A1 (en) 2003-05-02
ZA200200477B (en) 2003-06-25
MXPA02001088A (en) 2003-09-22
HUP0400540A2 (en) 2004-06-28
SK1512002A3 (en) 2002-11-06
BR0012896A (en) 2002-06-18
CN1377346A (en) 2002-10-30
AR032279A1 (en) 2003-11-05
JP2003506368A (en) 2003-02-18
WO2001009121A2 (en) 2001-02-08
KR20020091829A (en) 2002-12-06
NZ516850A (en) 2004-09-24
CN1193026C (en) 2005-03-16
HUP0400540A3 (en) 2004-09-28
WO2001009121A3 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
TR200200928T2 (en) 2-pyrazoline-5-on compositions
TR200003206T2 (en) Indole derivatives and their use in the treatment of malignant diseases and other diseases caused by pathological cell proliferation.
TR200102020T2 (en) W-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors.
TR200201505T2 (en) Pirazolopyrimidines as therapeutic agents
TR200101395T2 (en) 4-Aminopyrrolopyrimidines as kinase inhibitors
NO20070514L (en) Pyrrolotriazine kinase inhibitors
DK0939627T3 (en) Pentaflourobenzene sulfonamides and analogues
PT1242060E (en) TREATMENT OF THE METASTATIC DISEASE
BR0313396A (en) 3-pyrrolyl pyridopyrazoles and 3-pyrrolyl indazoles as kinase inhibitors
MA28279A1 (en) INDOLE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS, IN PARTICULAR IKK2 INHIBITORS
TR200101237T2 (en) Antralinic acid- and thioanthranilic acid-N-aryl amides
TR199900048T2 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
DE60015594D1 (en) IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS
YU21401A (en) Tetrahydropyridoethers
TR200103016T2 (en) Pirazolobenzodiazepines as CDK2 inhibitors
BR0007589A (en) Cell proliferation inhibitors
DE60002714D1 (en) SUBSTITUTED AZAOXINDOL DERIVATIVES
ES2249309T3 (en) COMPOUNDS OF 3,4-DIHIDRO- (1H) QUINAZOLIN-2-ONA AS INHIBITORS OF CSBP / P39 KINASA.
ATE341545T1 (en) QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS
BRPI0517921A (en) methods for preparing indazole compounds
ATE311389T1 (en) PRECURSOR OF IMIDAZOPYRIDINE DERIVATIVES
PT1147103E (en) FENANTRIDINE-N-OXIDES WITH PDE-IV INHIBITORS ACTIVITY
ATE269340T1 (en) THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
ATE287886T1 (en) USE OF 5-THIO, SULFINYL- AND SULFONYLPYRAZOLO 3,4-B) PYRIDINES AS CYCLINE-DEPENDENT KINASE INHIBITORS
EA200601176A1 (en) 3-CYANOHINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY